Skip to main content
TipRanks
Go Ultimate75% OFF

HOYA (HOCPY) AI Stock Analysis

38 Followers
HOCPY

HOYA

(Other OTC:HOCPY)

Select Model
Rating:82Outperform
Price Target:$171.00â–²(18.60% Upside)
Action:upgraded
Date:11/01/26

HOYA earns a high score on the strength of an outstanding financial profile: steady revenue compounding, expanding margins, a virtually debt-free balance sheet, return on equity near 28%, and cash flow that comfortably exceeds reported earnings. Technicals are supportive, with the price above all key moving averages and positive MACD momentum, though the short-term advance looks extended. The primary restraint is valuation — a P/E above 33 with only a 1.2% dividend yield leaves little margin for error, particularly as trailing revenue growth has slowed and results remain exposed to currency and semiconductor/eyewear cycles. With no earnings call commentary or corporate events available, the score rests on fundamentals, technicals and valuation.

Positive Factors
Strong ProfitabilityHOYA’s very high gross, operating, and net margins indicate substantial earnings power and differentiated product economics. Maintaining this profitability provides internal funding for innovation and expansion while offering resilience if demand growth remains moderate over the next several quarters.
Negative Factors
Slowing Revenue GrowthDecelerating top-line growth could limit future earnings expansion if HOYA cannot offset slower demand through new products, volume gains, or pricing. Even with strong margins, a prolonged slowdown would reduce operating leverage and make sustained profit growth more dependent on efficiency and mix.

HOYA (HOCPY) vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%25%30%HOCPY-2.81%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$48.85B
Dividend Yield
1.38%
Average Volume (3M)
32.60K
Price to Earnings (P/E)
27.6
Beta (1Y)
0.83
Revenue Growth
7.04%
EPS Growth
31.05%
Country
US
Employees
37,752
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

HOYA Business Overview & Revenue Model

Company Description

Globally recognized as a med-tech innovator, HOYA Corporation is a prominent provider of advanced technology and healthcare solutions worldwide. Its comprehensive portfolio of life care products encompasses vision correction items such as eyeglasses...

How the Company Makes Money

HOYA makes money primarily by selling products and solutions across its major business lines, with revenue generally generated through a mix of high-volume consumables and higher-value equipment. 1) Vision Care (eyeglass lenses): HOYA generates reven...

HOYA Financial Statement Overview

Summary

Exceptional across all three statements. Revenue has compounded past ¥1 trillion with operating margins near 35% and net margins around 28%, while net income has grown faster than sales, evidencing real operating leverage. The balance sheet is effectively debt-free (debt-to-equity of 0.04) with equity funding about 78% of assets and return on equity near 28% achieved without leverage. Cash flow is equally strong: operating cash flow of roughly ¥304 billion covers net income about 1.5x, and free cash flow of roughly ¥246 billion converts about 81% of earnings. Offsets are modest — trailing revenue growth has decelerated to low single digits, reported gross margins swing widely between fiscal years, and results remain sensitive to currency and semiconductor/eyewear cycles.

Income Statement

91Very Positive

Balance Sheet

94Very Positive

Cash Flow

90Very Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2026Mar 2025Mar 2024Mar 2023
Income Statement
Total Revenue927.15B885.82B1.00T762.61B734.10B670.33B
Gross Profit765.40B766.25B793.79B421.69B631.86B567.28B
EBITDA451.54B310.00B359.07B285.70B259.78B243.96B
Net Income253.01B202.10B268.35B181.38B168.64B164.51B
Balance Sheet
Total Assets1.31T1.23T1.31T1.20T1.03T992.84B
Cash, Cash Equivalents and Short-Term Investments580.98B538.53B576.58B525.16B426.27B426.63B
Total Debt41.46B37.28B42.42B29.24B24.58B21.60B
Total Liabilities264.40B262.65B267.05B241.36B213.72B203.78B
Stockholders Equity1.03T974.02B1.02T967.76B818.32B803.85B
Cash Flow
Free Cash Flow153.05B187.19B235.25B181.73B168.36B161.18B
Operating Cash Flow194.99B235.11B295.24B222.80B201.83B190.06B
Investing Cash Flow8.07B-33.19B-8.04B-35.81B-47.50B-29.30B
Financing Cash Flow-214.81B-190.35B-277.01B-110.89B-194.59B-106.72B

HOYA Technical Analysis

Technical Analysis SentimentNegative
Last Price144.18

Price Trends

50DMA153.86Negative
100DMA155.26Negative
200DMA164.82Negative

Market Momentum

MACD-3.15Positive
RSI39.34Neutral
STOCH45.43Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOCPY, the sentiment is Negative. The current price of 144.18 is below the 20-day moving average (MA) of 154.64, below the 50-day MA of 153.86, and below the 200-day MA of 164.82, indicating a bearish trend. The MACD of -3.15 indicates Positive momentum. The RSI at 39.34 is Neutral, neither overbought nor oversold. The STOCH value of 45.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HOCPY.

HOYA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HOCPY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ISRGISRG84Outperform$141.17B48.7117.03%―20.45%8.75%
HOCPYHOCPY82Outperform$49.43B27.6227.70%1.38%7.04%31.05%
BLCOBLCO65Neutral$7.40B-66.81-1.73%―8.88%63.73%
BDXBDX63Neutral$57.93B51.254.64%1.87%-7.40%-28.89%
COOCOO63Neutral$11.47B20.596.88%―4.73%43.89%
STAASTAA59Neutral$1.26B2503.000.15%―42.36%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%40%HOCPYBDXCOOISRGSTAABLCODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HOCPY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HOCPYHoya Corp144.18-3.21-2.18%
BDXBecton, Dickinson and Co212.7866.3845.34%
COOCooper Companies58.88-17.13-22.54%
ISRGIntuitive Surgical399.05-169.43-29.80%
STAAStaar Surgical Company24.22-2.32-8.74%
BLCOBausch + Lomb Corporation19.383.9325.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 01, 2026